MedTrace Logo

Ticagrelor Pharmacokinetics in NSTEMI

NCT02292277 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2016-05-23

No results posted yet for this study

Summary

Patients with myocardial infarction, which does not include all layers of the heart's muscle wall are common and they often receive pharmacological treatment with the platelet inhibiting drug ticagrelor. However, the drug uptake after an oral dose of 180mg ticagrelor has not been thoroughly studied in these patients.

The present study will evaluate ticagrelor uptake and platelet aggregation after a 180 mg loading dose ticagrelor in these patients.

Conditions

Interventions

DRUG

Ticagrelor

Oral loading dose of 180 mg ticagrelor.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Jan van der Linden, MD, PhD · Dept of Molecular Medicine and Surgery, Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-10-31
Completion
2016-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02292277 on ClinicalTrials.gov